Loading clinical trials...
Loading clinical trials...
A Randomized Sham-controlled Double-masked Phase 2a Study of the Efficacy, Safety and Tolerability of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema Who Have Had Prior Anti-vascular Endothelial Growth Factor Treatment
Conditions
Interventions
KVD001 Injection
Sham Procedure
Locations
35
United States
KalVista Investigative Site
Phoenix, Arizona, United States
KalVista Investigative Site
Phoenix, Arizona, United States
KalVista Investigative Site
Tucson, Arizona, United States
KalVista Investigative Site
Arcadia, California, United States
KalVista Investigative Site
Beverly Hills, California, United States
KalVista Investigative Site
Palm Desert, California, United States
Start Date
February 16, 2018
Primary Completion Date
October 10, 2019
Completion Date
October 10, 2019
Last Updated
January 28, 2021
NCT07449936
NCT07449923
NCT07228559
NCT05802329
NCT06781255
NCT06701721
Lead Sponsor
KalVista Pharmaceuticals, Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions